Sage Therapeutics Inc. shares (NASDAQ:SAGE) rose 15.4 percent to $86.71 on Tuesday after hitting a 52-week high on news that the company is accelerating plans to begin testing its most advanced compound, SAGE-547, in a new trial for the treatment of postpartum depression before the end of this year.